患者偏好证据应用于卫生技术评估的价值、方法及挑战  

The significance,approaches and challenges of integrating patient preference evidence into Health Technology Assessment

作　　者：刘世蒙 杨毅 孙辉[1,2,3] 明坚[1,2] 陈英耀[1,2] LIU Shi-meng;YANG Yi;SUN Hui;MING Jian;CHEN Ying-yao(School of Public Health, Fudan University, Shanghai 200032, China;NHC Key Laboratory of Health Technology Assessment (Fudan University), Shanghai 200032, China;Shanghai Health Development Research Center, Shanghai 201199, China)

机构地区：[1]复旦大学公共卫生学院,上海200032 [2]国家卫生健康委卫生技术评估重点实验室(复旦大学),上海200032 [3]上海市卫生和健康发展研究中心,上海201199

出　　处：《中国卫生政策研究》2022年第5期52-58,共7页Chinese Journal of Health Policy

基　　金：国家自然科学基金面上项目(72074047)。

摘　　要：当前,越来越多的国际卫生技术评估机构倡导在卫生技术评估(Health Technology Assessment,HTA)过程中整合患者偏好证据,从而使卫生决策的制定更加公开、透明和以患者为中心。HTA在我国已成为临床应用、医保准入以及定价等决策活动的关键手段,但关于患者偏好应用于HTA的价值以及如何在HTA中整合患者偏好证据等方面的研究还非常匮乏。本文从患者偏好应用于HTA的价值、现有途径与方法以及存在的挑战等维度进行分析总结,以期推动我国HTA科学应用患者偏好证据,为临床及卫生管理决策的制定提供更加综合、全面的证据信息。At present,more and more international HTA institutions advocates integrating patient preferences(PP)evidence into HTA process to make health decision making more informed,transparent and patient-centered.In China,HTA has become an important tool to help acquire new health technology,reimbursement decisions and pricing,however,there is little documentation and research about the importance of incorporating PP to HTA and how to integrate PP evidence into HTA.By analysing and summarizing the necessity,approaches,and challenges of integrating PP into HTA,this study aimed to promote the scientific integration of PP evidence into HTA process in China,so as to provide more comprehensive evidence information for clinical and health management decision making.

关 键 词：卫生技术评估 患者偏好 证据整合 

分 类 号：R197[医药卫生—卫生事业管理]